Is Furazolidone Therapy for Helicobacter pylori Effective and Safe?

Francesco, Vincenzo De; Ierardi, Enzo; Hassan, Cesare; Zullo, Angelo

doi:10.1007/s10620-009-0748-x

Cited by 9 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The very limited experience in children with a quadruple therapy containing furazolidone has yielded relatively good results (49). However, the inclusion of furazolidone in a treatment regimen for H. pylori infection is, at least, controversial, and it does not appear to be safe (50). Different studies have raised several concerns about this agent and its potential for possible genotoxic and carcinogenetic effects (50).…”

Section: Re-treatmentmentioning

confidence: 99%

“…However, the inclusion of furazolidone in a treatment regimen for H. pylori infection is, at least, controversial, and it does not appear to be safe (50). Different studies have raised several concerns about this agent and its potential for possible genotoxic and carcinogenetic effects (50). The FDA withdrew its approval for furazolidone in March 2005.…”

Section: Re-treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter Pylori Therapy in Children: Overview and Challenges

Chiesa

Pacifico

Anania

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Helicobacter pylori is one of the most common infections found in humans. It was first identified in 1982 and by 1989 had been associated with gastric inflammation and ulcers in adults and children. During the 1990's evidence emerged of its etiologic role in stomach cancers in adults. That the infection is common and may have serious consequences, has led to an avalanche of research during the last twenty years. During this time, there have been many studies on children which have sought an effective and safe treatment to eradicate the infection, but as yet, no therapy regimen has been found which is always effective and safe. This article provides information, from a pediatric point of view, on the major developments in the therapeutics and therapy of H. pylori infection. It examines first-line treatment regimens, evaluates the efficacy of the main drugs used in the management of (primary) H. pylori infection in children, assesses the potential for the use of probiotics and sequential therapy, examines therapeutic options after failure of initial treatment, and discusses factors affecting eradication rate, including antibiotic resistance, adherence to therapy, and bacterial factors.

show abstract

Section: Re-treatmentmentioning

confidence: 99%

Section: Re-treatmentmentioning

confidence: 99%

Helicobacter Pylori Therapy in Children: Overview and Challenges

Chiesa

Pacifico

Anania

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…A widely read letter to the editor stated that furazolidone had been removed from the US market because it was a proven carcinogen. [68] [83] carcinogen which is defined as "unclassifiable as to carcinogenicity in humans". [68] Clarithromycin-containing triple therapies are very effective regimens provided the appropriate doses and duration are used and local resistance to clarithromycin is low.…”

Section: Amoxicillinmentioning

confidence: 99%

Helicobacter pylori infection in India from a western perspective

Thirumurthi¹,

Graham²

2010

Indian J Med Sci

View full text Add to dashboard Cite

Helicobacter pylori is a common bacterial infectious disease whose manifestations predominately affect the gastrointestinal tract. India is the prototypical developing country as far as H. pylori infection is concerned and more than 20 million Indians are estimated to suffer from peptic ulcer disease. Considering the high level of Medicine and of the pharmaceutical industry, one would expect that India would be the source of much needed information regarding new therapies and approaches that remain effective in the presence of antimicrobial resistance, new methods to reliably prevent reinfection, and the development of therapeutic and preventive vaccines. Here, we discuss H. pylori as an Indian problem with an emphasis on H. pylori infection as a serious transmissible infectious disease. We discuss the pros and cons of eradication of H. pylori from the entire population and come down on the side of eradication. The available data from India regarding antimicrobial use and resistance as well as the effectiveness of various treatments is discussed. Rigorous ongoing studies to provide current regional antibiotic resistance patterns coupled with data concerning the success rate with different treatment regimens are needed to guide therapy. A systematic approach to identify reliably effective (e.g., 90% or greater treatment success) cost-effective regimens is suggested as well as details of regimens likely to be effective in India. H. pylori is just one of the health care problems faced in India, but one where all the resources are on hand to understand and solve it.

show abstract

“…Во всем мире продолжается неуклонный рост числа резистентных к кларитромицину штаммов H.pylori, что связано, по всей вероятности, с широким прменением этого антибиотика для лечения респираторных инфекций [8,9]. В одном из исследований, проведенном в Италии, показано, что за период с 1990 по 2005 г. показатели резистентности H.pylori к кларитромицину увеличились в этой стране вдвое [10]. Аналогичный феномен был обнаружен и в Англии, где резистентность к кларитромицину с 2002 по 2006 г. выросла на 57% [11].…”

unclassified

“…Сложным и до настояще-го времени не решенным остается вопрос о тактике веде-ния пациентов, у которых неэффективными оказываются оба курса терапии -первой и второй линии. В этой ситуации предлагается эмпирическое (без определения чувствительности) использование одного из следующих препаратов: рифабутина [19] или фуразолидона [10]. При применении рифабутина рекомендуется следующая схема: ИПП, рифабутин (150 мг), амоксициллин (1000 мг) 2 раза в день в течение 14 дней.…”

unclassified

Up-to-date standarts of eradication therapy. аre all the qUestions answered? R.A. AbdoulkhAkov, S.R. AbdoulkhAkov

AbdoulkhAkov¹,

AbdoulkhAkov²

2010

BCCM

View full text Add to dashboard Cite

Ложнопозитивные результаты чаще всего связаны с контаминацией материала микроорганизмами полости рта, глотки или желудка; наиболее частые причины ложноотрицательных результатов -кровотечение из верхних отделов желудочно-кишечного тракта, низкая плотность H.pylori в слизистой оболочке желудка после его резекции или проведенной ранее антихеликобак-терной терапии.Выбор метода выявления H.pylori определяется в зави-симости от клинической ситуации: в том случае, когда про-водится эндоскопическое исследование верхних отделов ЖКТ, предпочтительнее проведение быстрого уреазного теста в сочетании с гистологическим исследованием. По-следнее предполагает взятие по одному биоптату из ант-рального отдела и тела желудка для быстрого уреазного теста, а также из указанных отделов для гистологического исследования. Данная методика удовлетворяет требо-ваниям к получению двух положительных результатов при выявлении инфекции H.pylori. Единственным исклю-Т а б л и ц а 1

show abstract

Is Furazolidone Therapy for Helicobacter pylori Effective and Safe?

Cited by 9 publications

References 13 publications

Helicobacter Pylori Therapy in Children: Overview and Challenges

Helicobacter Pylori Therapy in Children: Overview and Challenges

Helicobacter pylori infection in India from a western perspective

Up-to-date standarts of eradication therapy. аre all the qUestions answered? R.A. AbdoulkhAkov, S.R. AbdoulkhAkov

Contact Info

Product

Resources

About